TMC125-C223: TMC125 in HIV-1 Infected Subjects

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2004
The purpose of this study is to investigate the ability of TMC125, a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), to lower the amount of virus in your blood when administered twice daily for 48 weeks.
Epistemonikos ID: 0f9a2439b5a8c972f276ed80bef9d5c720fbb823
First added on: Dec 01, 2021